RELEASE: The Michael J. Fox Foundation Awards Selonterra a $2,500,000 Grant

(Information sent by the signatory company).

RELEASE: The Michael J. Fox Foundation Awards Selonterra a $2,500,000 Grant

(Information sent by the signatory company)

- Michael J. Fox Foundation awards Selonterra a $2,500,000 grant for Parkinson's research

SAN MATEO, California, March 8, 2023 /PRNewswire/ -- Selonterra, Inc. (, a biotechnology company developing transformative therapies for neurodegenerative disorders, announces a US$2.5 million grant from the Michael J. Fox Foundation for Parkinson's Research (MJFF).

Selonterra focuses on neurodegenerative disorders with strong genetic links. The Selonterra team found that DNA changes associated with key genetic determinants in Parkinson's and Alzheimer's diseases control the expression of genes in their chromosomal neighborhood. These last genes are the true mediators of these diseases and offer new untapped targets for the development of therapies. The shared common pathways in these neurodegenerative disorders allow us to develop small molecules with the potential to profoundly change therapies for Parkinson's and Alzheimer's diseases.

Funding from the Michael J. Fox Foundation enables Selonterra to link novel targets to clinical dysfunctions in Parkinson's disease and optimize our small molecules toward clinical candidates.

"We are immensely grateful to receive this funding from the Michael J. Fox Foundation to support these completely untapped approaches with the potential for significant impact in Parkinson's disease patients," said Roman Urfer, PhD, founder and CEO of Selonterra.

"The contribution of genetics to Parkinson's disease is indisputable," said Anne Urfer-Buchwalder, PhD, founder and president of Selonterra. "In contrast to the involvement of the proteins encoded by these genetic variants, our focus on the DNA sequence and the genes that control these DNA variants offers fundamentally different therapeutic opportunities."

"MJFF greatly values ​​research that reexamines the biological underpinnings of Parkinson's disease and leverages that information for new treatment ideas. We are proud to support the work of researchers like the Selonterra team as they investigate new ways to meet unmet need." of people with Parkinson's," said Brian Fiske, PhD, MJFF Co-Scientific Director.

About Selonterra, Inc.

Selonterra, Inc. ( pursues transformative approaches to the development of therapies for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease. We harness human genetics, molecular pathway analysis, and gene regulatory networks to identify proprietary disease-causing mechanisms and molecular targets, and exploit these to discover effective therapies. Selonterra's founders and advisors are scientists and executives with decades of biotech and pharmaceutical experience complemented by a global network of partner companies.

Contact for investors and media:

T: ( 1) 650 206 7025E:

Keywords: Parkinson's disease; Alzheimer disease; Gene Regulation Networks; Neurodegenerative Disorders; human genetics

Logo -

View original content: